Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Open Access
- 29 September 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 14 (1), 129
- https://doi.org/10.1186/s12933-015-0294-0
Abstract
The traditional oral pharmacological therapy for type 2 diabetes mellitus (T2DM) has been based on the prescription of metformin, a biguanide, as first line antihyperglycemic agent world over. It has been demonstrated that after 3 years of treatment, approximately 50 % of diabetic patients could achieve acceptable glucose levels with monotherapy; but by 9 years this had declined to only 25 %. Therefore, the implementation of a combined pharmacological therapy acting via different pathways becomes necessary, and its combination with a compound of the sulfonylurea group was along decades the most frequently employed prescription in routine clinical practice. Meglitinides, glitazones and alpha-glucosidase inhibitors were subsequently developed, but the five mentioned groups of oral antihyperglycemic agents are associated with variable degrees of undesirable or even severe cardiovascular events. The gliptins—also called dipeptidyl peptidase 4 (DPP4) inhibitors—are an additional group of antidiabetic compounds with increasing clinical use. We review the status of the gliptins with emphasis on their capabilities to positively or negatively affect the cardiovascular system, and their potential involvement in major adverse cardiovascular events (MACE). Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin and vildagliptin are the compounds currently in clinical use. Regardless differences in chemical structure and metabolic pathways, gliptins as a group exert favorable changes in experimental models. These changes, as an almost general rule, include improved endothelial function, reduction of inflammatory markers, oxidative stress ischemia/reperfusion injury and atherogenesis. In addition, increased adiponectin levels and modest decreases in lipidemia and blood pressure were reported. In clinical settings, several trials—notably the longer one, employing sitagliptin, with a mean follow-up period of 3 years—did not show an increased risk for ischemic events. Anyway, it should be emphasized that the encouraging results from basic science were not yet translated into clinical evidence, probably due the multiple and pleiotropic enzymatic effects of DPP4 inhibition. Moreover, when employing saxagliptin, while the drug was not associated with an augmented risk for ischemic events, it should be pinpointed that the rate of hospitalization for heart failure was significantly increased. Gliptins as a group constitute a widely accepted therapy for the management of T2DM, usually as a second-line medication. Nonetheless, for the time being, a definite relationship between gliptins treatment and improved cardiovascular outcomes remains uncertain and needs yet to be proven.Keywords
This publication has 140 references indexed in Scilit:
- Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetesCardiovascular Diabetology, 2013
- Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemiaCardiovascular Diabetology, 2013
- Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trialDiabetes and Vascular Disease Research, 2013
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisCardiovascular Diabetology, 2013
- Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance databaseBMC Clinical Pharmacology, 2011
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated AngioedemaHypertension, 2009
- Sitagliptin, an dipeptidyl peptidase‐4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjectsBritish Journal of Clinical Pharmacology, 2008
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClinical Therapeutics, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJama-Journal Of The American Medical Association, 2007